Nutritional advice

Objectives:
What is the relationship between serum, dietary and urinary potassium and the risk of type 2 diabetes mellitus (T2DM)?  

Study design:
This review article included 8 prospective cohort studies involved 5,053 type 2 diabetes mellitus cases among 119,993 individuals.
The follow-up durations were from 5 to 18.1 years with a baseline age range from 18 to 95 years.
Serum potassium was measured using the ion-selective electrode method. Dietary potassium was estimated from food frequency questionnaire (FFQ). Urinary potassium samples were analyzed by potentiometric methods.
Most of the included studies provided risk estimates adjusted for age, sex, race, BMI and family history of diabetes.

Results and conclusions:
The investigators found in 5 studies involving 28,944 individuals and 3,849 type 2 diabetes mellitus cases, a non-significantly reduced risk of 21% [summary RR = 0.79, 95% CI = 0.60-1.04, I2 = 76.7%] for type 2 diabetes mellitus, when comparing the highest versus lowest serum potassium levels.
However, the sensitivity analysis did show a significant inverse association between serum potassium and type 2 diabetes mellitus risk [RR = 0.63, 95% CI = 0.52-0.73, I2 = 0%].

The investigators found in random dose-response meta-regression analysis a significantly reduced risk of 17% for type 2 diabetes mellitus [RR = 0.83, 95% CI = 0.73-0.95] per 1 mmol/L increase in serum potassium.

The investigators found in 6 studies involving 112,125 individuals and 4,573 type 2 diabetes mellitus cases, a non-significantly reduced risk of 7% [RR = 0.93, 95% CI = 0.81-1.06, I2 = 0.0%, p = 0.52] for type 2 diabetes mellitus, when comparing the highest versus lowest dietary potassium intake.
The sensitivity analysis did not significantly alter the association between dietary potassium and type 2 diabetes mellitus risk.

The investigators found there was no significant dose-response relationship between dietary potassium and type 2 diabetes mellitus risk [RR for every 1000mg increase dietary potassium per day = 1.00, 95% CI = 0.96-1.05].

The investigators found in 3 studies involving 4,376 individuals and 455 type 2 diabetes mellitus cases, a non-significantly reduced risk of 17% [RR = 0.83, 95% CI = 0.39-1.75, I2 = 73.9%, p = 0.02] for type 2 diabetes mellitus, when comparing the highest versus lowest urinary potassium levels.

The investigators found there was no significant dose-response relationship between urinary potassium levels and type 2 diabetes mellitus risk [RR for 10 mmol increase in urinary potassium per 24 hours = 1.00, 95% CI = 0.95-1.05].

The investigators concluded that serum potassium levels are linearly associated with the risk of type 2 diabetes mellitus, with each 1 mmol/L increase in serum potassium lowering the risk by 17%. However, neither dietary potassium nor urinary potassium shows any association with the risk of type 2 diabetes mellitus.

Original title:
Potassium measurements and risk of type 2 diabetes: a dose-response meta-analysis of prospective cohort studies by Peng Y, Zhong GC, […], Yang G.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725047/

Additional information of El Mondo:
Find more information/studies on type 2 diabetes and potassium right here.
 

Objectives:
Over the last 7 years there has been intense debate about the advice to reduce saturated fat and increase polyunsaturated fat to reduce cardiovascular (CVD) risk. Therefore, this review article (meta-analysis) has been conducted.

Does replacement of saturated fat with carbohydrate, polyunsaturated fatty acid (PUFA) or monounsaturated fatty acid (MUFA) reduce cardiovascular risk?

Study design:
This review article included cohort studies and intervention studies.

Results and conclusions:
The investigators found replacement of saturated fat with any carbohydrate, polyunsaturated fatty acid (PUFA) and monounsaturated fatty acid (MUFA) is associated with lower mortality with PUFA being more effective than MUFA [19% reduction versus 11%].

The investigators found per 5% of energy (5 En%) replacement of saturated fat with polyunsaturated fatty acid and fish oil significantly lowered risk of cardiovascular mortality with 28%.  

The investigators found replacing saturated fat with PUFA or MUFA was equally effective at reducing coronary heart disease (CHD) events

The investigators found replacement of saturated fat with whole grains significantly lowered coronary heart disease events while replacement with sugar and starch significantly increased coronary heart disease events.

The investigators found replacement of saturated fat with carbohydrate had no effect on coronary heart disease events or death.

The investigators found only PUFA replacement of saturated fat significantly lowered coronary heart disease events and cardiovascular and total mortality.

The investigators concluded reducing saturated fat and replacing it with carbohydrate will not lower coronary heart disease events or cardiovascular mortality although it will reduce total mortality. Replacing saturated fat with PUFA, MUFA or high-quality carbohydrate will lower coronary heart disease events.

Original title:
A systematic review of the effect of dietary saturated and polyunsaturated fat on heart disease by Clifton PM and Keogh JB.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/29174025

Additional information of El Mondo:
Find more information/studies on fat, carbohydrates and cardiovascular diseases right here.

Objectives:
What are the cardiovascular benefits of indiscriminate supplementation of omega-3 supplementation?

Study design:
This review article included 8 RCTs.

Results and conclusions:
The investigators found omega-3 supplementation significantly resulted in a 8% decrease of the risk of cardiac death, unless the patients are treated by statins.

The investigators found omega-3 supplementation prolonged quality adjusted life years by about a month. Old people gained less, whereas diabetes mellitus type 2 patients and people with history of cardiovascular events gained more.

The investigators concluded omega-3 supplementation decreases risk of cardiac death, unless the patients are treated by statins.

Original title:
The cardiovascular benefits of indiscriminate supplementation of omega-3 fatty acids; meta-analysis and decision-making approach by Leshno M, Goldbourt U, [...], Lichtenberg D.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/29171335

Additional information of El Mondo:
Find more information/studies on omega-3 fatty acids and cardiovascular diseases right here.

Objectives:
Beetroot is considered a complementary treatment for hypertension because of its high content of inorganic NO3.

The aim of this meta-analysis (review article) is to clarify several aspects of beetroot juice supplementation on systolic blood pressure (SBP) and diastolic blood pressure (DBP).

Study design:
This review article included 22 RCTs with a total of 47 intervention (n = 650) and 43 control (n = 598) groups.

Results and conclusions:
The investigators found overall, systolic blood pressure [-3.55 mmHg, 95% CI = -4.55 to -2.54 mmHg] and diastolic blood pressure [-1.32 mmHg, 95% CI = -1.97 to -0.68 mmHg] were significantly lower in the beetroot juice-supplemented groups than in the control groups.

The investigators found the mean difference of systolic blood pressure was larger between beetroot juice-supplemented and control groups in the longer than in the shorter (≥14 compared with 14 days) study durations [-5.11 compared with -2.67 mmHg].

The investigators found the mean difference of systolic blood pressure was larger between beetroot juice-supplemented and control groups in the highest compared with the lowest (500 compared with 70 and 140 mL/d] doses of beetroot juice [-4.78 compared with -2.37 mmHg].

The investigators found a positive correlation between beetroot juice doses and the mean differences of blood pressures.

The investigators found a smaller effect size of blood pressures after supplementation with higher NO3 (milligrams per 100 mL beetroot juice).

The investigators found a weak effect size in a meta-analysis of trials that used NO3-depleted beetroot juice as a placebo compared with other interventions [-3.09 compared with -4.51 mmHg for systolic blood pressure and -0.81 compared with -2.01 mmHg for diastolic blood pressure].

The investigators concluded beetroot juice supplementation, particularly 500 mL/d beetroot juice during at least 14 days, reduces blood pressure.

Original title:
The Nitrate-Independent Blood Pressure-Lowering Effect of Beetroot Juice: A Systematic Review and Meta-Analysis by Bahadoran Z, Mirmiran P, […], Ghasemi A.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/29141968

Additional information of El Mondo:
Find more information/studies on fruit, hypertension prevention and cardiovascular diseases right here.

Objectives:
What is the relationship of the intake of whole grains, refined grains, vegetables, fruits, nuts, legumes, eggs, dairy, fish, red meat, processed meat and sugar-sweetened beverages (SSBs) and the risk of hypertension?

Study design:
This review article included 28 prospective cohort studies.

Results and conclusions:
The investigators found in dose-response meta-analysis of 4 studies with 28,069 incident hypertension cases, a significantly reduced risk of 8% [RR = 0.92, 95% CI = 0.87-0.98, I2 = 88%, p 0.0001] for hypertension for 30 g/day whole grains. Significant means that there is an association with a 95% confidence.
The reduced risk was highest (15%) at 90 g/day whole grains.

The investigators found in dose-response meta-analysis of 6 studies, a significantly reduced risk of 3% [RR = 0.97, 95% CI = 0.96-0.99, I2 = 64%, p = 0.02] for hypertension for 100 g/day fruits.
The strongest risk reduction was 7% at 300 g/day fruits.

The investigators found in dose-response meta-analysis of 9 studies with 31,509 incident hypertension cases, a significantly reduced risk of 5% [RR = 0.95, 95% CI = 0.94-0.97, I2 = 0%, p = 0.50] for hypertension for 200 g/day dairy products.
The strongest risk reduction was 15% at 800 g/day dairy products.

The investigators found in dose-response meta-analysis of 7 studies with 97,745 incident hypertension cases, a significantly increased risk of 14% [RR = 1.14, 95% CI = 1.02-1.28, I2 = 88%, p 0.001] for hypertension for 100 g/day red meat.
The increased risk was highest (40%) at 200 g/day red meat.

The investigators found in dose-response meta-analysis of 4 studies, a significantly increased risk of 12% [RR = 1.12, 95% CI = 1.00-1.26, I2 = 82%, p 0.001] for hypertension for 50 g/day processed meat.

The investigators found in dose-response meta-analysis of 4 studies, a significantly increased risk of 7% [RR = 1.07, 95% CI = 1.04-1.10, I2 = 64%, p = 0.04] for hypertension for 250 mL/day sugar-sweetened beverages.
The increased risk was highest (13%) at 450 mL/day sugar-sweetened beverages.

The investigators found compared with nonconsumption, an intake of 2 servings red meat/d [170g, RR = 1.35], 1 serving processed meat/d [35g, RR = 1.07], 1 serving fish/d [100g, RR = 1.08] and 2 servings sugar-sweetened beverages/d [500mL, RR = 1.14 was associated with a 78% increased risk of hypertension. On the other hand, a risk reduction by 44% would be achieved by not consuming these foods (red meat, processed meat, fish and sugar-sweetened beverages).

The investigators concluded a daily dietary intake of 30g whole grains, 100g fruits, 200g dairy products reduce risk of hypertension, whereas a daily dietary intake of 100g red meat, 50g processed meat, and 250mL sugar-sweetened beverages increase risk of hypertension. These findings need to be seen under the light of very-low to low credibility of meta-evidence. However, the findings support the current dietary recommendations in the primary prevention of hypertension.

Original title:
Food Groups and Risk of Hypertension: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies by Schwingshackl L, Schwedhelm C, […], Boeing H.

Link:
http://advances.nutrition.org/content/8/6/793.long

Additional information of El Mondo:
Find more information/studies on different food groups, hypertension prevention and cardiovascular diseases right here.

Objectives:
Previous meta‐analyses on meat intake and risk of stroke did not report the effect of white meat (poultry meat, excluding fish) and did not examine stroke incidence and mortality separately. Therefore, this review article (meta-analysis) has been conducted.

What is the relationship of total (red and processed meat), red (unprocessed or fresh red meat) and processed (processed red meat) meat consumption along with white meat on risk of stroke incidence and mortality disease risk?

Study design:
This review article included 15 prospective cohort studies (254,742 participants with 9,522 stroke incidents and 487,150 participants with 12,999 cases of stroke mortality). The follow-up duration varied from 5.5 to 26 years.

There was no significant publication bias based on the Egger test except that the evaluation of total meat with stroke incidence reached the significance threshold.

The average score for study quality assessed by the Newcastle‐Ottawa Scale was 7.29 (range 7-8) for studies on meat consumption and stroke incidence and 6.87 (range 6-8) for those on stroke mortality.

Results and conclusions:
The investigators found that a high total meat (red and processed meat) consumption resulted in a significantly higher risk of 18% [pooled relative risk = 1.18, 95% CI = 1.09-1.28, I2 = 0%] for total stroke incidence. Significantly means that there is an association with a 95% confidence.

The investigators found that a high red meat consumption resulted in a significantly higher risk of 11% [pooled relative risk = 1.11, 95% CI = 1.03-1.20, I2 = 0%] for total stroke incidence.

The investigators found that a high processed meat consumption resulted in a significantly higher risk of 17% [pooled relative risk = 1.17, 95% CI = 1.08-1.25, I2 = 0%] for total stroke incidence.

The investigators found that a high white meat consumption resulted in a significantly lower risk of 13% [pooled relative risk = 0.87, 95% CI = 0.78-0.97, I2 = 0%] for total stroke incidence.

The investigators found, however, no significant associations between consumption of total [RR = 0.97, 95% CI = 0.85-1.11, I2 = 0%] or red meat [RR = 0.87, 95% CI = 0.64-1.18, I2 = 70.9%] and stroke mortality. No significant associations because RR of 1 was found in the 95% CI of 0.64 to 1.18. RR of 1 means no risk/association.

The investigators found that a high total meat consumption was associated with an increased risk of 41% for hemorrhagic stroke [RR = 1.41, 95% CI = 1.08-1.84, I2 = 0%], but no significant association was found between a high total meat consumption and ischemic stroke [RR = 1.16, 95% CI = 0.94-1.43, I2 = 40.6%].

The investigators found a positive association between total meat consumption and stroke incidence, regardless of sex, number of cases and follow‐up duration.

The investigators found when stratified by adjustment variables, studies that adjusted for family history of myocardial infarction, fruit and vegetable intake and use of aspirin showed a statistically significant relationship between total meat intake and risk of stroke compared with other studies that did not include those as adjustment variables.

The investigators found that a high red meat consumption was associated with an increased risk of 24% for ischemic stroke [RR = 1.24, 95% CI = 1.05-1.46, I2 = 17.7%], but no significant association was found between a high red meat consumption and hemorrhagic stroke [RR = 1.11, 95% CI = 0.89-1.38, I2 = 0%].

The investigators found that a high processed meat consumption was linked to neither ischemic [RR = 1.10, 95% CI = 0.96-1.27, I2 = 11.4%] nor hemorrhagic stroke [RR = 1.19, 95% CI = 0.95-1.49, I2 = 8.10%].

The investigators concluded that higher consumption of red or processed meat is associated with an increase in the risk of stroke, while higher intake of white meat is related to a reduction in stroke incidence. Therefore, recommendations for replacing proportions of red and processed meat to white meat for the prevention of stroke may be considered in clinical practice.

Original title:
Role of Total, Red, Processed, and White Meat Consumption in Stroke Incidence and Mortality: A Systematic Review and Meta-Analysis of Prospective Cohort Studies by Kim K, Hyeon J, […], Park SM.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634267/

Additional information of El Mondo:
Find more information/studies on meat consumption and cardiovascular diseases right here.

Objectives:
Dietary fiber intake, especially viscous soluble fiber, has been established as a means to reduce cardiometabolic risk factors. Whether this is true for blood pressure remains controversial. Therefore, this review article (meta-analysis) has been conducted.

Does viscous soluble fiber supplementation reduce cardiovascular disease risk?

Study design:
This review article included 22 (n = 1430) and 21 RCTs (N = 1343) for systolic blood pressure (SBP) and diastolic blood pressure (DBP), respectively.

5 types of viscous fiber supplementation were β-glucan from oats and barley, guar gum, konjac, pectin and psyllium.

Results and conclusions:
The investigators found viscous soluble fiber supplementation significantly reduced systolic blood pressure [MD = -1.59 mmHg, 95% CI = -2.72 to -0.46, I2 = 72%, p 0.01] and diastolic blood pressure [MD = -0.39 mmHg, 95% CI = -0.76 to -0.01, I2 = 67%, p 0.01] at a median dose of 8.7 g/day (1.45-30 g/day) over a median follow-up of 7-weeks.

The investigators found within the five fiber types, systolic blood pressure reductions were observed only for supplementation using psyllium fiber [MD = -2.39 mmHg, 95% CI = -4.62 to -0.17].

The investigators concluded 8.7 g/day viscous soluble fiber supplementation, particularly psyllium fiber during 7 weeks reduces systolic blood pressure (SBP) and diastolic blood pressure (DBP). Therefore, inclusion of viscous fiber to habitual diets may have additional value in reducing cardiovascular risk via improvement in blood pressure.

Original title:
The effect of viscous soluble fiber on blood pressure: A systematic review and meta-analysis of randomized controlled trials by Khan K, Jovanovski E, […], Vuksan V.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/29153856

Additional information of El Mondo:
Find more information/studies on fiber consumption, hypertension and cardiovascular diseases right here.

Objectives:
Elevated cholesterol has been linked to cardiovascular disease in adults and preclinical markers of atherosclerosis in children, thus reducing saturated (SFA) and trans-fatty acids (TFA) intake from an early age may help to reduce cholesterol and the risk of cardiovascular disease later in life. The World Health Organization (WHO) is currently updating its guidance on SFA and TFA intake in adults and children. Therefore, this review article (meta-analysis) has been conducted.

Does a diet with low saturated fatty acids reduce cholesterol and blood pressure in children and adolescents between 2 to 19 years of age?

Study design:
This review article included 8 RCTs (5 trials had a duration of 1 year and 3 had a duration of ≥ 1year with a total of 2,430 individual children and adolescents between 2 to 19 years of age) and 3 cohort studies.

Minimum duration was 13 days for RCTs and one year for cohort studies.

Saturated fatty acids intake was assessed using 24hr dietary recalls in 4 trials, 3-day diet records in 3 trials and food frequency questionnaires and/or checklists in 2 trials.

No trials were identified meeting the inclusion criteria for trans-fatty acids.

Publication bias was not assessed as the number of trials found was not sufficient to conduct funnel plot analyses for any outcome measure.

Results and conclusions:
The investigators found compared with control diets, there was a highly statistically significant effect of reduced saturated fatty acids intake on total cholesterol [MD = -0.16 mmol/L, 95% CI = -0.25 to -0.07, I2 = 64%], LDL cholesterol [MD = -0.13 mmol/L, 95% CI = -0.22 to -0.03, I2 = 77%] and diastolic blood pressure [MD = -1.45 mmol/L, 95% CI = -2.34 to -0.56].
The effects on cholesterol were greatest among those in which saturated fatty acids was replaced primarily with PUFA or MUFA and when the intervention group achieved a reduction in saturated fatty acids to below 10% of total energy intake.

The investigators found subgroup analysis of the effect of the initial lipid status of the participants showed a significantly different effect of saturated fatty acids reduction on total cholesterol [p = 0.05] between trials involving normolipidaemic/mixed status children [MD -0.21 mmol/L, 95% CI = -0.31 to -0.12] vs hyperlipidaemic children [MD = -0.08 mmol/L, 95% CI = -0.15 to -0.01].

The investigators found subgroup analysis of the effect of the initial lipid status of the participants showed the reduction in LDL cholesterol (bad cholesterol) was greater among the trials conducted in normolipidaemic/mixed status [MD -0.21 mmol/L, 95% CI = -0.30 to -0.13] vs hyperlipidaemic children [MD = -0.02 mmol/L, 95% CI = -0.14 to -0.11].

The investigators found there were no significant associations observed for HDL cholesterol (good cholesterol), triglycerides or apolipoproteins A1 or B.

The investigators found there were no significant associations observed between reduced saturated fatty acids intake and weight, height, body mass index (BMI) or waist circumference.

The investigators found there was no evidence of adverse effects of reducing saturated fatty acids intake in children on micronutrient intakes, cognitive development or sexual maturation in the small number of trials reporting these outcomes.  

The investigators concluded a diet with low saturated fatty acids reduces total cholesterol, LDL cholesterol and diastolic blood pressure in children and adolescents between 2 to 19 years of age without evidence of adverse effects on growth and development. The greatest effect on cholesterol occurred when saturated fatty acids was replaced with PUFA or a mixture of PUFA/MUFA and when saturated fatty acids intake was less than 10% of total energy intake. Therefore, dietary guidelines for children and adolescents should continue to recommend diets low in saturated fat.

Original title:
Health effects of saturated and trans-fatty acid intake in children and adolescents: Systematic review and meta-analysis by Morenga L and Montez JM.

Link:
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0186672

Additional information of El Mondo:
Find more information/studies on fat consumption, body mass index, hypertension, cholesterol and cardiovascular diseases right here.  

A diet with saturated fatty acids intake less than 10% of total energy intake is a diet with less than 10 En% saturated fat.
A diet with less than 10 En% saturated fat is a diet that is largely made up of meals/products with less than 10 En% saturated fat. Practically, this means that all meals/products that you eat on a daily basis should on average contain less than 10 En% saturated fat. Check here which products contain less than 10 En% saturated fat.

Objectives:
Despite growing evidence for food-based dietary patterns' potential to reduce cardiovascular disease risk, knowledge about the amounts of food associated with the greatest change in risk of specific cardiovascular outcomes and about the quality of meta-evidence is limited. Therefore, this review article (meta-analysis) has been conducted.

Which food-based dietary patterns reduce risk of cardiovascular diseases, such as coronary heart disease (CHD), stroke and heart failure (HF)?

Study design:
This review article included 123 prospective cohort studies.

Results and conclusions:
The investigators found whole grains significantly reduced risk of coronary heart disease with 5% [RR = 0.95, 95% CI = 0.92-0.98]. Significantly means that there is an association with a 95% confidence.

The investigators found whole grains significantly reduced risk of heart failure with 4% [RR = 0.96, 95% CI = 0.95-0.97]. Significantly because RR of 1 was not found in the 95% CI of 0.95 to 0.97. RR of 1 means no risk/association.

The investigators found vegetables significantly reduced risk of coronary heart disease with 3% [RR = 0.97, 95% CI = 0.96-0.99]. Significantly means it can be said with a 95% confidence that a intake of vegetables really decreased the risk of getting coronary heart disease with 3%.  

The investigators found fruits significantly reduced risk of coronary heart disease with 6% [RR = 0.94, 95% CI = 0.90-0.97].

The investigators found vegetables significantly reduced risk of stroke with 8% [RR = 0.92, 95% CI = 0.86-0.98].

The investigators found fruits significantly reduced risk of stroke with 10% [RR = 0.90, 95% CI = 0.84-0.97].

The investigators found nuts non-significantly reduced risk of coronary heart disease with 33% [RR = 0.67, 95% CI = 0.43-1.05]. Non-significantly means that there is no association with a 95% confidence.

The investigators found fish consumption significantly reduced risk of stroke with 14% [RR = 0.86, 95% CI = 0.75-0.99].

The investigators found fish consumption significantly reduced risk of heart failure with 20% [RR = 0.80, 95% CI = 0.67-0.95].

The investigators found egg significantly increased risk of heart failure with 16% [RR = 1.16, 95% CI = 1.03-1.31].

The investigators found red meat significantly increased risk of coronary heart disease with 15% [RR = 1.15, 95% CI = 1.08-1.23].

The investigators found red meat significantly increased risk of stroke with 12% [RR = 1.12, 95% CI = 1.06-1.17].

The investigators found red meat significantly increased risk of heart failure with 8% [RR = 1.08, 95% CI = 1.02-1.14].

The investigators found processed meat significantly increased risk of coronary heart disease with 27% [RR = 1.27, 95% CI = 1.09-1.49].

The investigators found processed meat significantly increased risk of stroke with 17% [RR = 1.17, 95% CI = 1.02-1.34].

The investigators found processed meat significantly increased risk of heart failure with 12% [RR = 1.12, 95% CI = 1.05-1.19].

The investigators found sugar-sweetened beverages significantly increased risk of coronary heart disease with 17% [RR = 1.17, 95% CI = 1.11-1.23].

The investigators found sugar-sweetened beverages significantly increased risk of heart failure with 7% [RR = 1.07, 95% CI = 1.02-1.12].

The investigators found sugar-sweetened beverages significantly increased risk of stroke with 8% [RR = 1.08, 95% CI = 1.05-1.12].

The investigators found there were clear indications for non-linear dose-response relationships between whole grains, fruit, nuts, dairy and red meat and coronary heart disease.

The investigators concluded there is a relationship between food-based dietary patterns and risk of cardiovascular diseases, with an increased risk for consumption of eggs, red meat, processed meat and sugar-sweetened beverages and a decreased risk for consumption of whole grains, vegetables, fruit and fish.

Original title:
Food groups and risk of coronary heart disease, stroke and heart failure: A systematic review and dose-response meta-analysis of prospective studies by Bechthold A, Boeing H, […], Schwingshackl L.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/29039970

Additional information of El Mondo:
Find more information/studies on food groups and cardiovascular diseases right here. 

Objectives:
The therapeutic efficacy of coenzyme Q10 on patients with cardiac failure remains controversial. Therefore, this review article (meta-analysis) has been conducted.

Do patients with heart failure benefit from coenzyme Q10 supplements?

Study design:
This review article included a total of 14 RCTs with 1064 patients in coenzyme Q10 (treatment) group and 1085 patients in placebo (control) group.

Egger’s test results showed no significant evidence of publication bias in either endpoint.

Results and conclusions:
The investigators found compared with placebo, coenzyme Q10 supplementation significantly decreased mortality risk with 31% [RR = 0.69, 95% CI = 0.50 to 0.95, p = 0.02, I2 = 0%].

The investigators found a greater improvement in exercise capacity was established in patients who used coenzyme Q10 than in those who used placebo [SMD = 0.62, 95% CI = 0.02 to 0.30, p = 0.04, I2 = 54%].

The investigators found patients who used coenzyme Q10 and placebo associated with similar left heart ejection fraction [SMD = 0.14, 95% CI = -0.08 to 0.37, p = 0.22, I2 = 54%].

The investigators found no significant difference between coenzyme Q10 and placebo for NYHA classification [SMD = -0.70, 95% CI = -1.92 to 0.51, p = 0.26, I2 = 89%].

The investigators concluded in patients with heart failure, the administration of coenzyme Q10 results in lower mortality and improved exercise capacity compared with the effects of placebo treatment.

Original title:
Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials by Lei L and Liu Y.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525208/

Additional information of El Mondo:
Find more information/studies on coenzyme Q10 and cardiovascular diseases right here. 

Objectives:
Several previous meta-analyses show a consistent inverse association between nut consumption and all-cause mortality, but the associations with cause-specific mortality remain uncertain. Therefore, this meta-analysis (review article) has been conducted.

Does nut consumption reduce all-cause and cause-specific mortality?

Study design:
This review article included 18 prospective cohort studies with 81,034 deaths.

Results and conclusions:
The investigators found random-effects meta-analysis of 18 studies with 81,034 deaths showed a significant reduced risk of 19% [summary RR = 0.81, 95% CI = 0.78-0.84] for all-cause mortality for high compared with low nut consumption. This significant reduced risk was broadly consistent within subgroups according to various study and population characteristics and within sensitivity analyses that took into account potential confounders.

The investigators found random-effects meta-analysis of 17 studies with 20,381 deaths showed a significant reduced risk of 25% [summary RR = 0.75, 95% CI = 0.71-0.79] for cardiovascular mortality for high compared with low nut consumption. This significant reduced risk was broadly consistent within subgroups according to various study and population characteristics and within sensitivity analyses that took into account potential confounders.

The investigators found random-effects meta-analysis of 14 studies with 10,438 deaths showed a significant reduced risk of 27% [summary RR = 0.73, 95% CI = 0.67-0.80] for coronary heart disease mortality for high compared with low nut consumption. This significant reduced risk was broadly consistent within subgroups according to various study and population characteristics and within sensitivity analyses that took into account potential confounders.

The investigators found random-effects meta-analysis of 13 studies with 4,850 deaths showed a significant reduced risk of 18% [summary RR = 0.82, 95% CI = 0.73-0.91] for stroke mortality for high compared with low nut consumption. This significant reduced risk was broadly consistent within subgroups according to various study and population characteristics and within sensitivity analyses that took into account potential confounders.

The investigators found random-effects meta-analysis of 11 studies with 21,353 deaths showed a significant reduced risk of 13% [summary RR = 0.87, 95% CI = 0.80-0.93] for cancer mortality for high compared with low nut consumption. This significant reduced risk was broadly consistent within subgroups according to various study and population characteristics and within sensitivity analyses that took into account potential confounders.

The investigators found peanut (5 studies) and tree nut (3 studies) consumption were similarly associated with mortality risks.

The investigators found dose-response analyses suggested evidence for nonlinear associations between nut consumption and mortality [p-nonlinearity 0.001 for all outcomes except cancer mortality], with mortality risk levelling off at the consumption of about 3 servings per week (12g/day).

The investigators concluded that nut consumption is associated with reduced all-cause and cause-specific mortality, with the strongest reduction for coronary heart disease (CHD) mortality. Both tree nuts and peanuts lower mortality and most of the survival benefits could be achieved at a relative low level of nut consumption (up to 12g/day).

Original title:
Nut consumption in relation to all-cause and cause-specific mortality: a meta-analysis 18 prospective studies by Chen GC, Zhang R, [...], Qin LQ.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/28875220

Additional information of El Mondo:
Find more information/studies on nut consumption, cancer, cardiovascular disease and stroke right here.
 

Objectives:
Anthocyanins are of interest due to their anti-oxidative and vasodilatory properties. Earlier reviews have shown that berries and other anthocyanin rich foods or extracts can improve vascular health. However, the effect of anthocyanins on vascular function has not yet been reviewed. Therefore, this review article (meta-analysis) has been conducted.

Does anthocyanin supplementation improve vascular function?

Study design:
This review article included 29 RCTs (15 were parallel and 14 were crossover designs).
Anthocyanin intakes ranged from 1 to 724 mg/day.
Most studies (n = 19) involved participants in the middle to older age group (mean age ≥ 40 years).
The number of participants that completed each study ranged from 10 to 146.
Intervention durations ranged from 1 h to 6 h in the acute studies and one week to six months in the chronic studies.

There was no publication bias.

Results and conclusions:
The investigators found compared to placebo-control, acute anthocyanin supplementation (1-8 h post consumption of anthocyanin doses between 7 and 724 mg) significantly improved FMD [SMD = 3.92%, 95% CI = 1.47 to 6.38, p = 0.002, I2 = 91.8%].
No improvements were observed in PAT-RHI [SMD = 0.08, 95% CI = -0.34 to 0.50, p = 0.71, I2 = 0%].
Collectively, (i.e., the pooling of studies using FMD and/or PAT-RHI) anthocyanins may improve vascular reactivity [overall SMD = 2.41, 95% CI = 0.91 to 3.91, p = 0.002, I2 = 92.6%].

The investigators found compared to placebo-control, acute anthocyanin supplementation (1-8 h post consumption of anthocyanin doses between 7 and 724 mg) also significantly improved arterial stiffness, using PWV [SMD = -1.27 m/s, 95% CI = -1.96 to -0.58, p = 0.000, I2 = 17.9%].

The investigators found pulse wave velocity was improved following acute anthocyanin supplementation only [SMD = -1.27 m/s, 95% CI = -1.96 to -0.58, p = 0.000, I2 = 17.8%]. 

The investigators found compared to placebo-control, chronic anthocyanin supplementation (one week to six months and used anthocyanin doses of 12 to 320 mg/day) significantly improved FMD [SMD = 0.84%, 95% CI = 0.55 to 1.12, p = 0.000, I2 = 62.5%].
Collectively (i.e., the pooling of studies using FMD and/or PAT-RHI), chronic anthocyanin supplementation may improve vascular reactivity [overall SMD = 0.77, 95% CI = 0.37 to 1.16, p = 0.000, I2 = 85.3%].

The investigators concluded that both acute and chronic anthocyanin supplementation improve vascular health, particularly with respect to vascular reactivity measured by FMD. However, more research is required to determine the optimal dosage and the long-term effects of anthocyanin consumption.

Original title:
The Effect of Anthocyanin-Rich Foods or Extracts on Vascular Function in Adults: A Systematic Review and Meta-Analysis of Randomised Controlled Trials by Fairlie-Jones L, Davison K, […], Hill AM.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579701/

Additional information of El Mondo:
Find more information/studies on flavonoids and cardiovascular diseases right here.  

Objectives:
Although epidemiological studies have examined the role of chocolate in preventing cardiometabolic disease, the results remain inconsistent. Therefore, this review article (meta-analysis) has been conducted.

Does chocolate consumption reduce risk of coronary heart disease (CHD), stroke and diabetes?

Study design:
This review article included 14 prospective cohort studies, with 508,705 participants from six countries and 7,267 coronary heart disease (CHD) cases, 8,197 stroke cases and 13,271 diabetes cases.
The follow-up duration of the studies ranged from 5 to 16 years.
One serving was defined as 30g of chocolate.
The majority of chocolate consumed in the included studies was milk or dark chocolate.

Results and conclusions:
The investigators found in 6 cohort studies for the highest versus lowest intake of chocolate a significant reduced risk of 10% for coronary heart disease [pooled RR = 0.90, 95% CI = 0.82-0.97, I2 = 24.3%, p = 0.25]. Leave-one-out sensitivity analysis had no significant influence on the pooled results.

The investigators found regarding CHD subtype, a significant reduced risk of 14% [RR = 0.86, 95% CI = 0.77-0.96] for myocardial infarction.

The investigators found for studies with follow-up duration of 10 years a significant reduced risk of 28% for coronary heart disease [RR = 0.72, 95% CI = 0.57-0.92].

The investigators found for studies with follow-up duration of ≥10 years a significant reduced risk of 8% for coronary heart disease [RR = 0.92, 95% CI = 0.86-0.99].

The investigators found in dose-response meta-analysis of 5 studies a curvilinear association between chocolate consumption and risk of coronary heart disease [p for nonlinearity = 0.006].

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 6% for coronary heart disease for 1 serving (30g) chocolate per week [RR = 0.94, 95 CI = 0.90-0.99].   

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 9% for coronary heart disease for 3 servings (90g) chocolate per week [RR = 0.91, 95 CI = 0.85-0.97].   

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 11% for coronary heart disease for 7 servings (210g) chocolate per week [RR = 0.89, 95 CI = 0.83-0.95].   

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 12% for coronary heart disease for 10 servings (300g) chocolate per week [RR = 0.88, 95 CI = 0.81-0.95].   

The investigators found in 8 reports from 7 studies for the highest versus lowest level of chocolate consumption a significant reduced risk of 16% for stroke [pooled RR = 0.84, 95% CI = 0.78-0.90, I2 = 0%, p = 0.49]. The pooled risk of total stroke was not obviously modified in the sensitivity analysis by excluding one study at a time
Egger’s test suggested the presence of publication bias [p = 0.008]. However, after introducing the “trim and fill” method to adjust this bias, the overall risk estimate remained significant in favor of chocolate intake [RR = 0.86, 95% CI = 0.79-0.92].

The investigators found with regard to stroke subtypes, a significant reduced risk of 13% [RR = 0.87, 95% CI = 0.78-0.96] for cerebral infarction and a significant reduced risk of 17% [RR = 0.83, 95% CI = 0.71-0.97] for hemorrhagic stroke.

The investigators found in the stratified analysis by gender, a significant reduced risk of 13% of total stroke for male [RR = 0.87, 95% CI = 0.79-0.97] and a significant reduced risk of 16% of total stroke for female [RR = 0.84, 95% CI = 0.74-0.94].

The investigators found a significant reduced risk of 44% for studies with follow-up durations of 10 years [RR = 0.56, 95% CI = 0.37-0.85].

The investigators found a significant reduced risk of 15% for studies with follow-up durations of ≥10 years [RR = 0.85, 95% CI = 0.79-0.91].

The investigators found in 7 reports from 6 studies a nonlinear correlation between chocolate intake and risk of stroke [p for nonlinearity = 0.001].

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 9% for stroke for 1 serving chocolate per week [RR = 0.91, 95% CI = 0.86-0.97].   

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 13% for stroke for 3 servings chocolate per week [RR = 0.87, 95% CI = 0.81-0.94].   

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 15% for stroke for 7 servings chocolate per week [RR = 0.85, 95% CI = 0.76-0.93].   

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 17% for stroke for 10 servings chocolate per week [RR = 0.83, 95% CI = 0.72-0.94].   

The investigators found in 4 studies using “trim and fill” method, for the highest versus lowest intake of chocolate, a non-significant reduced risk of 8% for diabetes [pooled RR = 0.92, 95% CI = 0.78-1.08].

The investigators found in stratified analysis by sex, a significant reduced risk of 21% [RR = 0.79, 95% CI = 0.65-0.96] for men and a non-significant reduced risk of 8% [RR = 0.92, 95% CI = 0.72-1.17] for women.
Similarly, the risks of diabetes were not different between subsets of studies with follow-up durations of below or over 10 years [p for interaction = 0.51].

The investigators found in dose-response meta-analysis of 6 reports, a curvilinear association between chocolate intake and risk of diabetes [p for nonlinearity 0.001].

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 20% for diabetes for 1 serving chocolate per week [RR = 0.80, 95% CI = 0.71-0.91]. Significant means that there is an association with a 95% confidence.

The investigators found in dose-response meta-analysis, compared with no intake, a significant reduced risk of 24% for diabetes for 3 servings chocolate per week [RR = 0.76, 95% CI = 0.63-0.91]. Significant because RR of 1 was not found in the 95% CI of 0.63 to 0.91. RR of 1 means no risk/association.

The investigators found in dose-response meta-analysis, compared with no intake, a non-significant reduced risk of 17% for diabetes for 7 servings chocolate per week [RR = 0.83, 95% CI = 0.67-1.03]. Non-significant means it cannot be said with a 95% confidence that 7 servings chocolate per week really decreased the risk of diabetes with 17%.

The investigators found in dose-response meta-analysis, compared with no intake, a non-significant reduced risk of 11% for diabetes for 10 servings chocolate per week [RR = 0.89, 95% CI = 0.69-1.16].   

The investigators found in general, the dose-response pattern was J-shaped and the peak reduction in diabetes risk occurred at an intake of 2 servings/week [RR = 0.75, 95% CI = 0.63-0.89], with no protective effects observed when consuming chocolate > 6 servings/week.

The investigators concluded that chocolate consumption confers reduced risks of coronary heart disease, stroke and diabetes. Consuming chocolate in moderation (1-6 servings/week or 30-180g) may be optimal for the prevention of these burdensome diseases. However, additional large prospective studies are required to confirm the observed benefits of chocolate in populations with different characteristics and to establish the optimum frequency of chocolate intake for preventing cardiometabolic disease.

Original title:
Chocolate Consumption and Risk of Coronary Heart Disease, Stroke, and Diabetes: A Meta-Analysis of Prospective Studies by Yuan S, Li X, […], Lu J.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537803/

Additional information of El Mondo:
Find more information/studies on chocolate, diabetes and cardiovascular diseases right here.

Objectives:
The clinical benefits of perioperative antioxidant vitamin therapy in cardiac patients remain controversial. Therefore, this review article (meta-analysis) has been conducted.

Do patients undergoing cardiac surgery benefit from perioperative antioxidant vitamin therapy?

Study design:
This review article included 12 RCTs with 1584 cardiac patients.

Results and conclusions:
The investigators found compared with placebo or no antioxidant vitamin therapy that administration of antioxidant vitamin therapy resulted in a significant reduction:
-in postoperative atrial fibrillation (POAF) [RR = 0.55, 95% CI = 0.42 to 0.73, p  0.0001];
-duration of hospital stay [MD = -0.68, 95% CI = -0.98 to -0.39, p  0.00001];
-intensive care unit length of stay [MD = -0.21, 95% CI = -0.30 to -0.12, p  0.00001] and;      
-intubation time [MD = -2.41, 95% CI = -3.83 to -0.98, p = 0.001].

The investigators also found a trend towards a decrease in postoperative complications [RR = 0.72, 95% CI = 0.48-1.08, p = 0.11] and duration of postoperative atrial fibrillation [MD = -1.950, 95% CI = -3.28 to 0.29, p = 0.10].

The investigators concluded that perioperative antioxidant vitamin therapy in patients undergoing cardiac surgery reduces the incidence of postoperative atrial fibrillation, duration of hospital stay, intensive care unit length of stay and intubation time.

Original title:
The clinical benefits of perioperative antioxidant vitamin therapy in patients undergoing cardiac surgery: a meta-analysis by Geng J, Qian J, […], Shen Z.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/28645181

Additional information of El Mondo:
Find more information/studies on antioxidant and cardiovascular diseases right here.

Objectives:
Studies implicate choline and betaine metabolite trimethylamine N-oxide (TMAO) in cardiovascular disease (CVD). Therefore, this review article (meta-analysis) has been conducted.

Is there an association between choline and betaine dietary intake and cardiovascular disease?

Study design:
This review article included a total of 6 prospective cohort studies comprising 18,076 incident cardiovascular disease events, 5,343 cardiovascular disease deaths among 184,010 participants.

There was no evidence for heterogeneity among studies.
Only 2 studies provided data on phosphatidylcholine and cardiovascular disease mortality.

Results and conclusions:
The investigators found in random effects meta-analysis, incident cardiovascular disease was not associated with choline [RR = 1.00, 95% CI = 0.98-1.02] or betaine [RR = 0.99, 95% CI = 0.98-1.01] dietary intake.
Results did not vary by study outcome (incident coronary heart disease, stroke, total cardiovascular disease).

The investigators found random effects meta-analysis did not support an association between choline and cardiovascular disease mortality [RR = 1.09, 95% CI = 0.89-1.35], but one study supported a positive association and there was significant heterogeneity [I2 = 84%, p 0.001].

The investigators concluded that there is no association between dietary choline/betaine intake with incident cardiovascular disease, but further research into choline and cardiovascular disease mortality are needed.

Original title:
Dietary Choline and Betaine and Risk of CVD: A Systematic Review and Meta-Analysis of Prospective Studies by Meyer KA and Shea JW.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/28686188

Additional information of El Mondo:
Find more information/studies on choline and cardiovascular diseases right here.

Objectives:
Controversy exists on the association between alcohol consumption and risk of heart failure (HF). Therefore, this review article (meta-analysis) has been conducted.

Is there an association between alcohol consumption and risk of heart failure?

Study design:
This review article included a total of 13 prospective cohort studies, with 13,738 heart failure cases among 355,804 participants.

Results and conclusions:
The investigators found light alcohol drinking (0.1-7 drinks/week) significantly reduced risk of heart failure with 14% [RR = 0.86, 95% CI = 0.81-0.90]. However, there was no statistically significant association between moderate (7.1-14 drinks/week), high (14.1-28 drinks/week), or heavy (>28 drinks/week) alcohol consumption and heart failure risk.

The investigators found former drinking significantly increased risk of heart failure with 22% [RR = 1.22, 95% CI = 1.11-1.33] compared with never or occasional drinking.

The investigators concluded that light alcohol drinking (0.1-7 drinks/week) is associated with a lower risk of heart failure, while former drinking is associated with a higher risk of heart failure.

Original title:
Alcohol consumption and risk of heart failure: Meta-analysis of 13 prospective studies by Susanna C. Larsson, […], Alicja Wolk

Link:
http://www.sciencedirect.com/science/article/pii/S0261561417301681

Additional information of El Mondo:
Find more information/studies on alcohol consumption and cardiovascular diseases right here.

Objectives:
Recent evidence has suggested that flavonoid and lignan intake may be associated with decreased risk of chronic and degenerative diseases. Therefore, this review article (meta-analysis) has been conducted.

Does dietary flavonoid intake reduce risk of all-cause and cardiovascular disease mortality?

Study design:
This review article included 22 prospective cohort studies.

Results and conclusions:
The investigators found when compared with lower consumption, high consumption of total flavonoids was associated with a significant decreased risk of 26% for all-cause mortality [risk ratio = 0.74, 95% CI = 0.55-0.99].

The investigators found a 100-mg/day increment in dietary total flavonoids intake led to a (linear) decreased risk of 6% and 4% of all-cause and cardiovascular disease mortality, respectively.

The investigators found among flavonoid classes, significant results were obtained for intakes of flavonols, flavones, flavanones, anthocyanidins and proanthocyanidins.

The investigators found limited evidence was available on lignans intake and all-cause mortality.

The investigators concluded that higher dietary flavonoids intakes - at least 100-mg/day of flavonols, flavones, flavanones, anthocyanidins or proanthocyanidins - are associated with decreased risk of all-cause and cardiovascular disease mortality.

Original title:
Dietary Flavonoid and Lignan Intake and Mortality in Prospective Cohort Studies: Systematic Review and Dose-Response Meta-Analysis by Grosso G, Micek A, […], Giovannucci EL.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/28472215

Additional information of El Mondo:
Find more information/studies on flavonoids and cardiovascular diseases right here.

Objectives:
Increased dietary potassium intake is thought to be associated with low blood pressure (BP). Whether potassium supplementation may be used as an antihypertensive agent is a question that should be answered. Therefore, this review article (meta-analysis) has been conducted.

Does potassium supplementation reduce blood pressure among patients with essential hypertension (SBP ≥140 mmHg and DBP ≥90 mmHg)?

Study design:
This review article included 23 trials (9 parallel and 14 crossover randomized placebo-controlled clinical trials with a minimum of 4 weeks of therapy to ensure that the intervention had sufficient time to produce an effect) involving 1,213 patients with essential hypertension (SBP ≥140 mmHg and DBP ≥90 mmHg).

The result of meta-regression revealed that the association between potassium dosage, follow-up period and mean age were not statistically significant; therefore they did not play an important role in the heterogeneity across studies.

There was no publication bias.

Results and conclusions:
The investigators found that potassium supplementation significantly reduced systolic blood pressure (SBP) of patients with essential hypertension with 4.25 mmHg [95% CI = -5.96 to -2.53, I2 = 41%].

The investigators found that potassium supplementation significantly reduced diastolic blood pressure (DBP) of patients with essential hypertension with 2.53 mmHg [95% CI = -4.05 to -1.02, I2 = 65%].

The investigators found in 8 RCTs when compared to baseline, the mean changes in systolic blood of patients with essential hypertension was -8.89 mmHg [95% CI = -13.67 to -4.11] significantly higher in the intervention group (group taking potassium supplements) than the control group. 

The investigators found in 8 RCTs when compared to baseline, the mean changes in diastolic blood pressure of patients with essential hypertension was -6.42 mmHg [95% CI = -10.99 to -1.84] significantly higher in the intervention group (group taking potassium supplements) than the control group. 

The investigators found in subgroup analysis that the mean difference in systolic blood of patients with essential hypertension was -2.64 mmHg [95% CI = -5.25 to -0.03] in America, -4.56 mmHg [95% CI = -6.51 to -2.62) in Europe and -5.21 mmHg [95% CI = -9.63 to -0.79] in Asia.

The investigators found a dose-response relationship between potassium intake and reduction in systolic and diastolic blood pressure (low-dose (50 mmol/day), moderate-dose (50-99 mmol/day) and high-dose (≥100 mmol/day)).

The investigators concluded that potassium supplementation for at least 4 weeks reduces blood pressure of patients with essential hypertension and therefore, can be recommended as an adjuvant antihypertensive agent for patients with essential hypertension (SBP ≥140 mmHg and DBP ≥90 mmHg).

Original title:
Oral potassium supplementation for management of essential hypertension: A meta-analysis of randomized controlled trials by Poorolajal J, Zeraati F, […], Maleki A.

Link:
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0174967

Additional information of El Mondo:
Find more information/studies on hypertension and potassium right here.

Objectives:
The findings of prospective cohort studies are inconsistent regarding the association between dietary magnesium intake and serum magnesium concentration and the risk of hypertension. Therefore, this review article (meta-analysis) has been conducted.

Do dietary magnesium intake and serum magnesium concentrations reduce risk of hypertension?

Study design:
This review article included 10 cohort studies, including 20,119 cases of hypertension and 180,566 participants.

The range of dietary magnesium intake was 96-25 mg/day and serum magnesium levels were 0.66-0.95 mmol/L.

The funnel plot showed reasonable symmetry, with no evidence of publication bias (Egger’s test p = 0.95 and Begg’s test p = 0.71).

Results and conclusions:
The investigators found when comparing the highest to the lowest category of dietary magnesium consumption, a significant reduced risk of 8% for hypertension [pooled RR = 0.92, 95% CI = 0.86-0.98].

The investigators found for every 100 mg/day increment in dietary magnesium intake a significant reduced risk of 5% for hypertension [pooled RR = 0.95, 95% CI = 0.90-1.00, I2 = 39.3%, p = 0.13].
The reduced hypertension risk associated with 100 mg/day was tended to be observed when the duration of follow-up was more than 8 years and when the results were adjusted separately for calcium, sodium, fiber, cholesterol, saturated fat intake or smoking.

The investigators found the dose-response meta-analysis suggested a marginal linear relationship between dietary magnesium intake and hypertension risk [p for linearity = 0.057].

The investigators found no association between serum magnesium concentrations and reduced risk of hypertension [pooled RR = 0.91, 95% CI = 0.80-1.02, p = 0.10, I2 = 0%, p = 0.48].

The investigators concluded that increased dietary magnesium intake is associated with lower risk of hypertension in a linear dose-response pattern. However, there is no association between serum magnesium concentration and risk of hypertension.

Original title:
Dose-response relationship between dietary magnesium intake, serum magnesium concentration and risk of hypertension: a systematic review and meta-analysis of prospective cohort studies by Han H, Fang X, […], Cao Y.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420140/

Additional information of El Mondo:
Find more information/studies on hypertension and magnesium right here.

Objectives:
Heart failure (HF) remains a major health problem affecting 5.7 million adults in USA. Data on the association of egg consumption with incident heart failure have been inconsistent. Therefore, this review article (meta-analysis) has been conducted.

Does egg consumption increase incident heart failure in the general population?

Study design:
This review article included 4 prospective cohort studies with a total of 105,999 subjects and 5,059 cases of new onset heart failure.

There was no evidence of publication bias on funnel plot analysis as supported by the Egger’s test (p = 0.68).

Results and conclusions:
The investigators found when comparing the highest (≥1/day) to the lowest category of egg consumption, a significant increased risk of 25% [pooled RR = 1.25, 95% CI = 1.12-1.39, p = 0.00, I2 = %] for heart failure.

The investigators found that sensitivity analysis (stratification by excluding studies with men/women, 20 years of follow-up duration, US/Non-US studies) did not alter the main conclusion.

The investigators concluded that at least 1 egg per day increases heart failure risk in the general population. Further studies are warranted to explore the underlying biological mechanisms.

Original title:
Egg Consumption and Incidence of Heart Failure: A Meta-Analysis of Prospective Cohort Studies by Khawaja O, Singh H, […], Djoussé L.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367008/

Additional information of El Mondo:
Find more information/studies on cardiovascular diseases right here.

Objectives:
Previous systematic reviews and meta-analyses have evaluated the association of dairy consumption and the risk of cardiovascular disease (CVD). However, the findings were inconsistent. No quantitative analysis has specifically assessed the effect of yogurt intake on the incident risk of cardiovascular disease. Therefore, this review article (meta-analysis) has been conducted.

Is yogurt intake associated with a lower incident risk of cardiovascular disease?

Study design:
This review article included 9 prospective cohort studies involving a total of 291,236 participants. Follow-up durations ranged between 10.2 and 17.3 years. The baseline age of the participants ranged from ≥21 to ≥55 years. Yogurt intake was assessed by a food-frequency questionnaire (FFQ).

There was no publication bias.

Results and conclusions:
The investigators found when compared with the lowest category, highest category of yogurt consumption was not significantly related with the incident risk of cardiovascular disease [RR = 1.01, 95% = 0.95-1.08, I2 = 52%]. Not significantly because RR of 1 was found in the 95% CI of 0.95 to 1.08. RR of 1 means no risk/association.

The investigators found in the stratified analysis by type of outcome, the pooled RR of yogurt consumption was 1.04 [95% = 0.95 to 1.15] for CHD, RR = 1.02 [95% CI = 0.92 to 1.13] for stroke and RR = 0.87 [95% CI = 0.77 to 0.98] for the incident CVD events.

However, the investigators found intake of ≥200 g/day yogurt was significantly associated with a lower risk of 8% [RR = 0.92, 95% CI = 0.85 to 1.00] for cardiovascular disease in the subgroup analysis.

The investigators concluded that a daily dose of ≥200 g yogurt intake is associated with a lower incident risk of cardiovascular disease. Further cohort studies and randomized controlled trials are still demanded to establish and confirm the observed association in populations with different characteristics.

Original title:
Consumption of Yogurt and the Incident Risk of Cardiovascular Disease: A Meta-Analysis of Nine Cohort Studies by Wu L and Sun D.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372978/

Additional information of El Mondo:
Find more information/studies on cardiovascular diseases and consumption of dairy products right here.
 

Objectives:
Hypertension is a major risk factor for cardiovascular disease, myocardial infarction, stroke and renal failure. Sesame consumption may benefit blood pressure (BP) due to its high polyunsaturated fatty acids, fibre, phytosterol and lignans content. To clarify this association, this review article (meta-analysis) has been conducted.

Does sesame consumption reduce blood pressure?

Study design:
This review article included 8 controlled trials with a total of 843 participants.

Results and conclusions:
The investigators found that sesame consumption significantly reduced systolic blood pressure with 7.83 mmHg [95% CI = -14.12 to -1.54, p  0.05, I2 = 99%].

The investigators found that sesame consumption significantly reduced diastolic blood pressure with 5.83 mmHg [95% CI = -9.58 to -2.08, p  0.01, I2 = 98%].

However, to reduce the heterogeneity, the meta-analysis was limited to high methodology quality trials (n = 4), which resulted in a significant reduction of 3.23 mmHg in systolic blood pressure [95% CI = -5.67 to -0.79, I2 = 33%] and a non-significant reduction of 2.08 mmHg in diastolic blood pressure [95% CI = -4.85 to 0.69, I2 = 62%].

The investigators concluded that sesame consumption reduces the systolic blood pressure but not the diastolic blood pressure. However, further investigations with larger sample sizes and better methodology quality are required to confirm the blood pressure lowering effect of sesame consumption.

Original title:
Can sesame consumption improve blood pressure? A systematic review and meta-analysis of controlled trials by Khosravi-Boroujeni H, Nikbakht E, [...], Khalesi S.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/28387047

Additional information of El Mondo:
Find more information/studies on cardiovascular diseases and how to reduce a high blood pressure right here.
 

Objectives:
Does higher lycopene exposure decrease risk of cardiovascular diseases (CVD)?

Study design:
This review article included 14 observational studies.
Subgroup analyses showed that retrospective and low quality studies were statistically significant sources of heterogeneity.

Results and conclusions:
The investigators found higher lycopene exposure significantly reduced risk of cardiovascular diseases with 17% [pooled risk ratio = 0.83, 95% CI = 0.76-0.90]. Findings were similar restricting to dietary studies [RR = 0.87, 95% CI = 0.79-0.96] and biomarker studies [RR = 0.74, 95% CI = 0. 62-0.87].

The investigators found higher dietary lycopene intake significantly reduced risk of coronary heart disease with 13% [RR = 0.87, 95% CI = 0.76-0.98]. However, the reduced risk was not significant for higher lycopene biomarker concentrations.

The investigators found higher dietary lycopene intake significantly reduced risk of stroke with 17% [RR = 0.83, 95% CI = 0.69-0.96].

The investigators found higher lycopene biomarker concentrations significantly reduced risk of stroke with 35% [RR = 0.65, 95% CI = 0.42-0.87].

The investigators concluded both higher dietary lycopene intake and higher lycopene biomarker concentrations are inversely associated with a lower risk of cardiovascular diseases. Further well-designed randomized clinical trials are required to assess the role of lycopene on cardiovascular diseases.

Original title:
Lycopene and risk of cardiovascular diseases: A meta-analysis of observational studies by Song B, Liu K, […], Xu Y.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/28318092

Additional information of El Mondo:
Find more information/studies on cardiovascular diseases and lycopene right here.
Lycopene is a carotenoid and is responsible for the yellow colour in tomatoes. Carotenoids are antioxidants.

Objectives:
Different adiposity measures have been associated with increased risk of atrial fibrillation, however, results have previously only been summarized for BMI. Therefore, this review article (meta-analysis) has been conducted.

Is there an association between different adiposity measures and risk of atrial fibrillation?

Study design:
This review article included 25 prospective studies with 83,006 cases among 2,405,381 participants.

Results and conclusions:
The investigators found every 5 unit increment in BMI significantly increased risk of atrial fibrillation with 28% [RR= 1.28, 95% CI = 1.20-1.38, I2 = 97%].

The investigators found every 10 cm increase in waist circumference significantly increased risk of atrial fibrillation with 18% [95% CI = 1.12-1.25, I2 = 73%, n = 5].

The investigators found every 10 cm increase in hip circumference significantly increased risk of atrial fibrillation with 32% [95% CI = 1.16-1.51, I2 = 91%, n = 3].

The investigators found every 0.1 unit increase in waist-to-hip ratio significantly increased risk of atrial fibrillation with 9% [95% CI = 1.02-1.16, I2 = 44%, n = 4].

The investigators found every 5 kg increase in fat mass significantly increased risk of atrial fibrillation with 9% [95% CI = 1.02-1.16, I2 = 94%, n = 4].

The investigators found every 10% increase in fat percentage nonsignificantly increased risk of atrial fibrillation with 10% [95% CI = 0.92-1.33, I2 = 90%, n = 3]. Nonsignificantly because RR of 1 can be found in the 95% CI of 0.92 to 1.33. RR of 1 means no risk.

The investigators found every 5 kg increase in weight significantly increased risk of atrial fibrillation with 10% [95% CI = 1.08-1.13, I2 = 74%, n = 10].

The investigators found every 5% increase in weight gain nonsignificantly increased risk of atrial fibrillation with 8% [95% CI = 0.97-1.19, I2 = 86%, n = 2]. Nonsignificantly means, there is no association at a 95% confidence.

The investigators found the association between BMI and atrial fibrillation was nonlinear [p nonlinearity 0.0001] with a stronger association at higher BMI levels. However, increased risk was observed even at a BMI of 22-24 compared to 20.

The investigators concluded general and abdominal adiposity and higher body fat mass increase risk of atrial fibrillation.

Original title:
Body mass index, abdominal fatness, fat mass and the risk of atrial fibrillation: a systematic review and dose-response meta-analysis of prospective studies by Aune D, Sen A, […], Vatten LJ.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/28194602

Additional information of El Mondo:
Find here more information/studies about cardiovascular diseases and overweight.

Objectives:
Do consuming tomato products and lycopene supplementation reduce cardiovascular risk among adult subjects >18 years of age?

Study design:
This review article included 21 studies.

Results and conclusions:
The investigators found consuming tomato was associated with a significant reduction of 0.22 mmol/L in LDL-cholesterol [p = 0.006]. Significant means, there is an association at a 95% confidence.

The investigators found consuming tomato was associated with a significant reduction of 0.25 in plasma IL-6 concentration [p = 0.03].

The investigators found consuming tomato was associated with a significant improvement of 2.53% in flow-mediated dilation (FMD) [p = 0.01].

The investigators found lycopene supplementation reduced systolic blood pressure with 5.66 mmHg [p = 0.002].

The investigators found no other outcome was significantly affected by these interventions.

The investigators concluded consuming tomato products and lycopene supplementation had positive effects on blood lipids, blood pressure and endothelial function. These results support the development of promising individualised nutritional strategies involving tomatoes to tackle cardiovascular diseases.

Original title:
Tomato and lycopene supplementation and cardiovascular risk factors: A systematic review and meta-analysis by Cheng HM, Koutsidis G, […], Lara J.

Link:
https://www.ncbi.nlm.nih.gov/pubmed/28129549

Additional information of El Mondo:
Find here more information/studies about vegetable consumption, carotenoids and cardiovascular diseases.

Impaired endothelial function is an early indicator of atherosclerosis. Endothelial function is often quantified by flow-mediated dilation (FMD), which represents the endothelium-dependent relaxation of a conduit artery-typically the brachial artery - due to an increased blood flow. Flow-mediated dilation (FMD) is endothelium-dependent and can be assessed by ultrasound in the brachial artery.